Literature DB >> 7653696

Sertraline for social phobia: a double-blind, placebo-controlled crossover study.

D J Katzelnick1, K A Kobak, J H Greist, J W Jefferson, J M Mantle, R C Serlin.   

Abstract

OBJECTIVE: The authors examined the efficacy of sertraline in the treatment of social phobia.
METHOD: In a double-blind crossover study, 12 outpatients were randomly assigned to 10 weeks of sertraline (50-200 mg/day, flexible dosing) and 10 weeks of placebo.
RESULTS: A statistically significant improvement in scores on the Liebowitz Social Anxiety Scale was found with sertraline but not with placebo. There was no significant difference between scores obtained with computer- and clinician-administered versions of the Liebowitz Social Anxiety Scale, and the majority of patients preferred to be interviewed by the computer.
CONCLUSIONS: Sertraline seems a safe and effective treatment for social phobia, and computer administration may be a preferable mode of assessment with socially phobic patients.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7653696     DOI: 10.1176/ajp.152.9.1368

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  24 in total

Review 1.  Toward an integrative understanding of social phobia.

Authors:  D Li; P Chokka; P Tibbo
Journal:  J Psychiatry Neurosci       Date:  2001-05       Impact factor: 6.186

2.  Second-generation antidepressants in social anxiety disorder: meta-analysis of controlled clinical trials.

Authors:  Gabriela Bezerra de Menezes; Evandro Silva Freire Coutinho; Leonardo F Fontenelle; Paula Vigne; Ivan Figueira; Márcio Versiani
Journal:  Psychopharmacology (Berl)       Date:  2010-12-22       Impact factor: 4.530

Review 3.  Social anxiety disorder : current treatment recommendations.

Authors:  Jacqueline E Muller; Liezl Koen; Soraya Seedat; Dan J Stein
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 4.  Efficacy and tolerability of second-generation antidepressants in social anxiety disorder.

Authors:  Richard A Hansen; Bradley N Gaynes; Gerald Gartlehner; Charity G Moore; Ruchi Tiwari; Kathleen N Lohr
Journal:  Int Clin Psychopharmacol       Date:  2008-05       Impact factor: 1.659

Review 5.  A review of the epidemiology and approaches to the treatment of social anxiety disorder.

Authors:  L Sareen; M Stein
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

6.  The International Multicenter Clinical Trial Group on Moclobemide in Social Phobia. Moclobemide in social phobia. A double-blind, placebo-controlled clinical study.

Authors: 
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1997       Impact factor: 5.270

Review 7.  Anxiety disorders in older adults.

Authors:  J A Sable; D V Jeste
Journal:  Curr Psychiatry Rep       Date:  2001-08       Impact factor: 5.285

Review 8.  Social anxiety disorder: recent findings in the areas of epidemiology, etiology, and treatment.

Authors:  C Blanco; K Nissenson; M R Liebowitz
Journal:  Curr Psychiatry Rep       Date:  2001-08       Impact factor: 5.285

Review 9.  A risk-benefit assessment of buspirone in the treatment of anxiety disorders.

Authors:  J C Pecknold
Journal:  Drug Saf       Date:  1997-02       Impact factor: 5.606

Review 10.  Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders.

Authors:  Martin A Katzman; Pierre Bleau; Pierre Blier; Pratap Chokka; Kevin Kjernisted; Michael Van Ameringen; Martin M Antony; Stéphane Bouchard; Alain Brunet; Martine Flament; Sophie Grigoriadis; Sandra Mendlowitz; Kieron O'Connor; Kiran Rabheru; Peggy M A Richter; Melisa Robichaud; John R Walker
Journal:  BMC Psychiatry       Date:  2014-07-02       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.